Benchmark reiterated a buy rating on TScan Therapeutics, while MarketBeat provided stock average ratings.
3 reports, 1 independent
Updated Sep 4
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Benchmark reiterated a buy rating on TScan Therapeutics, while MarketBeat provided stock average ratings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Benchmark
venture capital firm
- The Bank of England, FED, and market experts are discussing how the ongoing Iran conflict and geopolitical tensions are driving up energy costs and influencing global financial rates.
- MarketBeat published a buy rating and target price increase for a company, with disclosures made under a Rule 10b5-1 trading plan.
-
MarketBeat
American personal finance blog
Related events
- MarketBeat provides stock rating data for Vivos Therapeutics, which is listed on Nasdaq.
- MarketBeat reported a Moderate Buy consensus rating for Genelux, while Benchmark reissued a speculative buy rating, and an insider sold shares.
- MarketBeat reported the stock average rating for Range Capital Acquisition Corp., a company that trades on the Nasdaq exchange.
- Analyst ratings published on MarketBeat for Monopar Therapeutics, which trades on the Nasdaq stock exchange.
- MarketBeat reported consensus ratings, Geode Capital Management raised its stake, Citigroup reissued a buy rating, and Benchmark restated a speculative buy rating regarding Intensity Therapeutics.